Multifunctional nanomedicine prototypes acting as prophylactics and virus-assisted targeted drug delivery vehicle (NANOPROV)

作为预防剂和病毒辅助靶向药物输送载体的多功能纳米药物原型(NANOPROV)

基本信息

  • 批准号:
    MR/Y50337X/1
  • 负责人:
  • 金额:
    $ 22.48万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2024
  • 资助国家:
    英国
  • 起止时间:
    2024 至 无数据
  • 项目状态:
    未结题

项目摘要

Unmet need. Viral infections are a global threat and the source of substantial social and economic burden. There is an increasing trend in the emergence and re-emergence of new viruses with high infectivity and mortality rates. Lessons learned from past pandemics, e.g. the global pandemic of SARS-CoV-2, demonstrate that a substantial amount of investment is needed to refine the science and technology to develop new early treatment antivirals. These antivirals should be based on a plug-in technology to be rapidly repurposed for treating the next fast-spreading virus and successfully managing pandemics. Approach and market. Among different technologies, pharmaceuticals based on nanoparticles show a high added value with an estimated compound annual growth rate of 22%. Protein-based nanopharmaceuticals are estimated to have a market size of $ 15 billion. NANOPROV will create novel protein-based prophylactic nanomedicines. The primary target group (> 8 million individuals in the UK alone) will be public servants and immunocompromised patients (e.g. cancer patients) and those requiring primary care. Innovative solution and background. NANOPROV will use a plug-in nanocage technology we have patented and built upon available data regarding antiviral binding proteins. It creates proof-of-concept efficacious antiviral prophylactic nanocages for early treatment. The plug-in technology can be quickly modified using genetic engineering and repurposed to create prophylactic nanocages against a new rapidly spreading virus. The project will generate the proof of concept product for developing inhalable formulations and preclinical tests. Our plug-in nanocage technology is based on the ubiquitous iron-storage protein of life ferritin. This naturally occurring nanocage protein is biocompatible, safe and stable and has shown an acceptable safety profile for making other therapeutics, such as vaccines.Team and environment. NANOPROV is a unique collaboration between experts in ferritin nanocages and those in antimicrobial therapeutics working at King's College London and the UK Health Security Agency (UKHSA). The Team has extensive experience developing antimicrobial products and collaborates with world-leading experts in inhalation drug delivery, formulation, and manufacturing and with biopharmaceutical companies. Expected impact. NANOPROV will refine the science and technology for developing early treatment protein-based nanopharmaceuticals. This unique cross-fertilisation of expertise and experience will create prototype antiviral nanomedicines and technological advances for rapid repurposing to counter a fast-spreading new virus. It will generate confidence in using our nanocage technology to develop other nanomedicines, including multivalent mosaic vaccines and multivalent anti-cancer immunotherapeutics.
未得到满足的需求。病毒感染是一种全球性威胁,是重大社会和经济负担的来源。具有高传染性和高死亡率的新病毒的出现和重新出现有增加的趋势。从过去的大流行中吸取的经验教训,例如SARS-CoV-2的全球大流行,表明需要大量投资来完善科学和技术,以开发新的早期治疗抗病毒药物。这些抗病毒药物应该基于一种插入式技术,以便迅速改变用途,以治疗下一种快速传播的病毒并成功地管理流行病。方法和市场。在不同的技术中,基于纳米颗粒的药物显示出高附加值,估计复合年增长率为22%。基于蛋白质的纳米药物的市场规模估计为150亿美元。NANOPROV将创造基于蛋白质的新型预防性纳米药物。主要目标群体(仅在英国就有800万人)将是公务员和免疫功能受损的患者(例如癌症患者)和那些需要初级护理的人。创新的解决方案和背景。NANOPROV将使用我们拥有专利的插入式纳米笼子技术,并建立在有关抗病毒结合蛋白的现有数据基础上。它为早期治疗创造了概念验证有效的抗病毒预防性纳米笼。这种插件技术可以利用基因工程进行快速修改,并重新调整用途,以创建针对一种新的快速传播的病毒的预防性纳米笼子。该项目将产生概念验证产品,用于开发可吸入制剂和临床前试验。我们的插入式纳米笼技术是基于生命铁蛋白这种普遍存在的储铁蛋白。这种自然产生的纳米笼蛋白具有生物相容性、安全性和稳定性,并已显示出可接受的用于制造其他疗法的安全性,如疫苗、团队和环境。NANOPROV是铁蛋白纳米笼专家与伦敦国王学院和英国卫生安全局(UKHSA)抗菌疗法专家之间的独特合作。该团队在开发抗微生物产品方面拥有丰富的经验,并与吸入性药物输送、配方和制造方面的世界领先专家以及生物制药公司合作。预期的影响。NANOPROV将完善开发早期治疗蛋白质纳米药物的科学和技术。这种专业知识和经验的独特交叉融合将创造出抗病毒纳米药物的原型和技术进步,以快速重新调整用途,以对抗快速传播的新病毒。它将使人们对使用我们的纳米笼技术开发其他纳米药物产生信心,包括多价马赛克疫苗和多价抗癌免疫疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kourosh Ebrahimi其他文献

Kourosh Ebrahimi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

超顺磁性氧化铁-量子点双显像荷电量可控性正电荷纳米囊泡用于干细胞移植的MRI活体示踪
  • 批准号:
    81071208
  • 批准年份:
    2010
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目

相似海外基金

Molecular strategy for developing instant nanomedicine
开发即时纳米药物的分子策略
  • 批准号:
    EP/Z532952/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.48万
  • 项目类别:
    Research Grant
Creation of PROTAC-based nanomedicine against glioblastoma
创建基于 PROTAC 的抗胶质母细胞瘤纳米药物
  • 批准号:
    24K18566
  • 财政年份:
    2024
  • 资助金额:
    $ 22.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
探索 ATR 和 PARP 抑制剂用于卵巢癌治疗:一种创新方法
  • 批准号:
    494635
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
    Operating Grants
Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer
用于转移性结直肠癌化疗免疫治疗的肿瘤靶向多模态纳米配位聚合物
  • 批准号:
    10639649
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
Multimodal Label-Free Nanosensor for Single Virus Characterization and Content Analysis
用于单一病毒表征和内容分析的多模式无标记纳米传感器
  • 批准号:
    10641529
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
Therapeutic nanoscale matrimeres
治疗性纳米级基质
  • 批准号:
    10650665
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
A novel framework for nanomedicine development
纳米医学开发的新框架
  • 批准号:
    10715013
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
一种用于治疗富含基质的胰腺癌的新型双载体超小纳米药物
  • 批准号:
    10759720
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
Surface exosome integrin profiling to predict organotropic metastasis of breast cancer
表面外泌体整合素分析预测乳腺癌的器官转移
  • 批准号:
    10654221
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
纳米免疫药物靶向肿瘤微环境治疗神经胶质瘤
  • 批准号:
    10743942
  • 财政年份:
    2023
  • 资助金额:
    $ 22.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了